Weidmann P, Hasler L, Gnädinger M P, Lang R E, Uehlinger D E, Shaw S, Rascher W, Reubi F C
J Clin Invest. 1986 Mar;77(3):734-42. doi: 10.1172/JCI112368.
Since mammalian atria were recently found to contain vasoactive and natriuretic peptides, we investigated the following in normal humans: plasma human atrial natriuretic peptide concentrations, effective renal plasma flow (ERPF), glomerular filtration rate (GFR), urinary water and electrolyte excretion, blood pressure (BP), and catecholamine, antidiuretic hormone (ADH), angiotensin II, and aldosterone levels before, during, and after intravenous administration of the newly synthetized alpha-human atrial natriuretic peptide (alpha hANP). In 10 subjects alpha hANP given as an initial bolus of 50 micrograms followed by a 45-min maintenance infusion at 6.25 micrograms/min increased plasma alpha hANP from 58 +/- 12 to 625 +/- 87 (mean +/- SEM) pg/ml; caused an acute fall in diastolic BP (-12%, P less than 0.001) and a hemoconcentration (hematocrit +7%, P less than 0.01) not fully explained by a negative body fluid balance; increased GFR (+15%, P less than 0.05) despite unchanged or decreased ERPF (filtration fraction +37%, P less than 0.001); augmented (P less than 0.05- less than 0.001) urinary chloride (+317%), sodium (+224%), calcium (+158%), magnesium (+110%), phosphate excretion (+88%), and free water clearance (from -0.76 to +2.23 ml/min, P less than 0.001) with only little change in potassium excretion; and increased plasma norepinephrine (P less than 0.001) while plasma and urinary epinephrine and dopamine, and plasma ADH, angiotensin II, and aldosterone levels were unchanged. The magnitude and pattern of electrolyte and water excretion during alpha hANP infusion could not be accounted for by increased GFR alone. Therefore, in normal man, endogenous alpha hANP seems to circulate in blood. alpha hANP can cause a BP reduction and hemoconcentration which occur, at least in part, independently of diuresis and are accompanied by sympathetic activation. An increase in GFR that occurs in the presence of unchanged or even decreased total renal blood flow is an important but not sole mechanism of natriuresis and diuresis induced by alpha hANP in man.
由于最近发现哺乳动物心房含有血管活性肽和利钠肽,我们对正常人体进行了以下研究:静脉注射新合成的α-人心房利钠肽(α-hANP)之前、期间和之后的血浆人心房利钠肽浓度、有效肾血浆流量(ERPF)、肾小球滤过率(GFR)、尿水和电解质排泄、血压(BP)以及儿茶酚胺、抗利尿激素(ADH)、血管紧张素II和醛固酮水平。在10名受试者中,以50微克的初始推注剂量给予α-hANP,随后以6.25微克/分钟的速度进行45分钟的维持输注,使血浆α-hANP从58±12增加到625±87(平均值±标准误)皮克/毫升;导致舒张压急性下降(-12%,P<0.001)和血液浓缩(血细胞比容+7%,P<0.01),负性体液平衡不能完全解释这种情况;尽管ERPF不变或降低(滤过分数+37%,P<0.001),GFR仍增加(+15%,P<0.05);尿氯(+317%)、钠(+224%)、钙(+158%)、镁(+110%)、磷酸盐排泄(+88%)和自由水清除率(从-0.76至+2.23毫升/分钟,P<0.001)增加(P<0.05 - <0.001),而钾排泄仅有轻微变化;血浆去甲肾上腺素增加(P<0.001),而血浆和尿肾上腺素、多巴胺以及血浆ADH、血管紧张素II和醛固酮水平不变。α-hANP输注期间电解质和水排泄的幅度和模式不能仅用GFR增加来解释。因此,在正常人体中,内源性α-hANP似乎在血液中循环。α-hANP可导致血压降低和血液浓缩,至少部分独立于利尿作用发生,并伴有交感神经激活。在总肾血流量不变甚至降低的情况下GFR增加是α-hANP在人体中诱导利钠和利尿的重要但非唯一机制。